Every correction moved the price upward, which means published 'cheapest' figures across this category are systematically low.
We verified fifteen programme prices against the provider's own published material this month. Fourteen needed correcting, and every correction moved the number up.
The scale is not trivial. Strut Health was carried at $199 and publishes $325. TrimRx was carried at $179 and publishes $349. Sprout Health was carried at $199 and publishes $299. MEDVi was carried at $179 and is listed at $399. IVIM was carried at $245 with no membership and charges $133 plus a mandatory $74.99 membership.
Two errors were the same mistake twice: a programme's semaglutide price published in its tirzepatide column. Yucca Health's $146 and Oak Longevity's $130 were both semaglutide figures. Semaglutide is consistently cheaper than tirzepatide, so that error always understates.
The pattern has a cause. Round-ups quote promotional first-month rates, bundle rates and medication-only figures that exclude mandatory memberships, and then present them as ongoing all-in prices. Every one of those distortions pushes the same direction.
If you are comparing programmes anywhere, including here, check the figure against the provider's own page and ask what it costs at 10 mg including every fee. Our tables now label which prices we have verified and which we have not.
Sources
- Provider published pricing pages, accessed 5 August 2026
- Our open dataset, with per-record verification status — source
Dated 2026-08-05. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.